表紙
市場調査レポート

後成的修飾スクリーニング動向

Epigenetic Modification Screening Trends 2014

発行 HTStec Ltd 商品コード 304885
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
後成的修飾スクリーニング動向 Epigenetic Modification Screening Trends 2014
出版日: 2014年06月03日 ページ情報: 英文
概要

当レポートでは、HTStecが実施した産業規模の世界的なエピジェネティクス修飾(後成的修飾)スクリーニングに関するオンラインベンチマーキング調査結果に基づき、エピジェネティクス修飾アッセイにおける現在の実務・嗜好、エピジェネティクスタンパク質に対する薬剤スクリーニングの将来のユーザー要件などを分析し、お届けいたします。

  • エグゼクティブサマリー
  • 目次
  • 調査方法
  • 回答者の主要なグループ活動・調査への回答
  • 回答者の出身地域
  • 回答者の企業または組織
  • 回答者の役職
  • 回答者の主要なグループ活動
  • 回答者の主要な調査領域
  • 現在のエピジェネティクス酵素スクリーニングアッセイ利用
  • エピジェネティクス標的の現況に関する意見
  • エピジェネティクス修飾アッセイを用いた治療/疾病分野
  • エピジェネティクス修飾研究に与えられるプライオリティレベル
  • 現在最も関心のある主要なエピジェネティクス修飾クラス
  • 研究中の主要なエピジェネティクス修飾クラス(1),(2)
  • 用いるエピジェネティクス修飾の主要ソース/起点
  • エピジェネティクス修飾アッセイを用いた創薬プロセスにおけるステージ
  • 適切な生化学的アッセイを持つエピジェネティクス修飾タンパク質
  • 適切なセルラーアッセイを持つエピジェネティクス修飾タンパク質
  • 調査結果のサマリー(1)
  • 内部作業向けの好きな生化学的アッセイフォーマット
  • テストをアウトソースする際の好きな生化学的アッセイフォーマット
  • 内部作業向けの好きなセルラーアッセイフォーマット
  • テストをアウトソースする際の好きなセルラーアッセイフォーマット
  • エピジェネティクス修飾アッセイ向けの好きな生化学的フォーマット
  • エピジェネティクス修飾アッセイ向けの好きなセルラーフォーマット
  • エピジェネティクス酵素アッセイ向けに最も一般的に用いられる基質
  • エピジェネティクス修飾タンパク質アッセイ開発における最も重要な課題
  • エピジェネティクス修飾タンパク質が経験する特定のアッセイ課題
  • エピジェネティクス修飾アッセイの調査を進めるために必要な新しいツール
  • エピジェネティクス修飾タンパク質スクリーニングの主な抑制因子
  • 過去2年間のエピジェネティクス修飾スクリーニングアッセイの抑制因子の変化
  • 社内エピジェネティクス修飾研究をサポートするFTEの数
  • 社内で研究されたエピジェネティクス修飾標的の数
  • エピジェネティクス修飾の年間一次スクリーン(HTS)数
  • 一次エピジェネティクス修飾スクリーンあたりのウェル(容器)数
  • エピジェネティクス修飾標的の一次スクリーンへのアプローチ
  • エピジェネティクス一次スクリーニングの生化学/酵素アッセイの割合
  • 調査結果のサマリー(2)
  • エピジェネティクス修飾アッセイ試薬予算
  • コンポーネントのエピジェネティクス修飾試薬予算の内訳
  • エピジェネティクス修飾アッセイ試薬市場推計(1)-(3)
  • エピジェネティクス修飾アッセイ試薬の主要ソース(1)-(2)
  • エピジェネティクス修飾スクリーニングアッセイのウェル1個当たりのコスト
  • エピジェネティクス修飾研究回答者がアウトソースしたい面
  • エピジェネティクス修飾一次スクリーニングアッセイのアウトソースの割合
  • エピジェネティクス修飾プロファイリングアッセイのアウトソースの割合
  • アウトソースエピジェネティクス修飾テストの予算
  • アウトソースエピジェネティクス修飾テスト市場の推計(1)-(2)
  • アウトソースエピジェネティクスプロファイリングの好みのプロバイダー(1)-(2)
  • エピジェネティクス修飾アッセイにおける改善要件・アンメットニーズ
  • 調査結果のサマリー(3)
目次

Executive Summary

This market report summarizes the results of HTStec's 3nd industry-wide global web-based benchmarking survey on epigenetic modification screening carried out in May 2014.

The survey was initiated by HTStec as part of its tracking of this emerging life science marketplace and to update HTStec's previous report (June 2012). The questionnaire was compiled to meet the needs, requirements and interests of the epigenetic modification vendor community. The objective was to comprehensively document current practices and preferences in epigenetic modification assays, and to understand future user requirements for drug screening against epigenetic proteins both internally and at fee-for-service providers.

Equal emphasis was given to soliciting opinion from Pharma, Biotech and Academic Research market segments in both North America and Europe.

The survey looked at the following aspects of epigenetic modification screening, as practiced today (2014) and in some cases as predicted for the future (2016): opinion on the current status of epigenetic targets; key diseases/therapeutic area(s) investigating epigenetic modification; level of priority for epigenetic modification research; epigenetic modification classes of greatest interest, and where respondents have investigated assay feasibility or already performed in house or outsourced testing; main source/origin of epigenetic proteins used; stages in the drug discovery process using biochemical assays and/or cellular assays for epigenetic modification; epigenetic modifications proteins with adequate biochemical and cellular assays; preferred biochemical and cellular assay format/detection technologies for internal work and when outsourcing testing against epigenetic modifications proteins; substrates most commonly used for epigenetic assays; the challenges of assay development of epigenetic modification proteins; new tools required to drive the investigation of epigenetic modification assays; what limits epigenetic modification screening; aspects of epigenetic modification drug discovery that are most limiting today; where the situation concerning the main limitations of epigenetic modification screening assays has improved in the past 2 years; number of FTE devoted to epigenetic modification research and different targets supported; number of epigenetic modification primary screens and wells per screen; approach to the primary screening (HTS) of epigenetic targets; proportion of epigenetic primary screens that are biochemical assays; in house epigenetic modification assay reagent budget and breakdown into components purchased; main suppliers of reagents and tools used to assay epigenetic modifications in house; average material cost per well of epigenetic modification screening assays; interest in outsourcing epigenetic modification research; proportion of epigenetic modification testing outsourced and number of wells outsourced; budget for outsourcing epigenetic modification assays and services; preferred fee-for-service providers for outsourced epigenetic modification profiling assays; and unmet needs in epigenetic enzyme assays and screening today.

The main questionnaire consisted of 29 multi-choice questions and 2 open-ended questions. In addition, there were 9 questions related solely to survey demographics.

The survey collected 91 validated responses, of these 65% provided comprehensive input.

Survey responses were geographically split: 65% North America; 25% Europe; 7% Asia (excluding Japan); 2% Japan; and 1% China.

Survey respondents were drawn from persons or groups performing epigenetic modification screening assays or planning future investigation in this area.

Respondents represented 43 University/Research Institute/Government Lab/Not-for-Profit Facilities; 17 Biotech; 12 Large Pharma; 6 Academic Screening Centers; 4 CROs; 4 Others; 3 Medium-Small Pharma; 1 Biopharma and 1 Agrochemical/Agri-Biotech.

Most survey respondents had a senior job role or position which was in descending order: 21 research scientists/associates; 15 senior scientists/researchers; 11 others; 9 principal investigators; 9 professors/ assistant professors; 6 post-docs; 6 department heads; 5 section/group leaders; 5 directors; and 4 lab managers.

Respondents represented the followings labs: 26 basic research; 15 with a combination of drug discovery roles; 12 assay development; 12 primary screening (HTS); 9 therapeutic areas (target ID/validation); 7 hits-to-leads (lead optimization); 6 others; 2 secondary screening; 1 compound profiling; 1 leads-to-candidate (ADME tox/preclinical research).

Survey results were expressed as an average of all survey respondents. In addition, where appropriate the data was reanalyzed after sub-division into the following 5 survey groups: 1) Pharma; 2) Biotech; 3) Academic Research; 4) Europe; and 5) North America.

The main research discipline of survey respondents was biology.

55% of respondents were currently routinely undertaking epigenetic modification screening assays, the reminder were planning future investigation.

The majority opinion of respondents on the current status of epigenetic targets was ‘maybe a major new category for successful new drug research, but more work is needed'.

The majority of respondents were targeting epigenetic assays within the oncology therapeutic area.

Most respondents had a medium level of priority for epigenetic modification research.

The epigenetic modification class rated of most interest/investigated was histone methyltransferases.

The main sources/origins of epigenetic proteins used today (2014) were commercial sources.

Epigenetic modification assays were most used/investigated in basic research.

The epigenetic modification proteins that respondents feel have most adequate biochemical and cellular assays were histone methyltransferases.

The preferred biochemical assay formats for different epigenetic modification proteins was ELISA for internal work and mass-spec (label-free) for outsourced testing.

The preferred cellular assay formats for different epigenetic modification proteins was ELISA for internal work and chromatin immunoprecipitation (ChIP-Seq) for outsourced testing.

Respondents most commonly used peptides as substrates for their epigenetic assays.

Specificity was ranked as the most important challenge of epigenetic modification assay development.

Only a minority had encountered specific assay challenges when working with epigenetic enzymes.

Availability of good antibodies was rated the most limiting (major obstacle) in the exploitation of epigenetic modification targets today.

The aspect of epigenetic modification drug discovery ranked most limiting was getting selectivity.

Some improvement in the limitations of epigenetic modification assays was seen in the past 2 years.

A median of 1-5 FTE's were allocated to support in house epigenetic modification research in 2014.

A median of 1-5 different epigenetic targets/projects/programs were undertaken in house in 2014.

A median of 1-5 epigenetic modification primary screens, each with 1K-5K wells were done in 2014.

The preferred approach to primary screening of epigenetic modification targets was to screen small focused compound sets or decks.

A median of 21-30% of all epigenetic primary screens were enzyme/biochemical assays in 2014.

A median budget of $5K-$25K/lab was allocated for epigenetic enzyme assay reagents in 2014.

A bottom-up model developed around respondent's annual budget for epigenetic modification assay reagents estimated the global market to be around $52M in 2014. The greatest share of this market was allocated to assay specific probes and biochemical assay kits.

The most used commercial sources of reagents and tools for in house epigenetic modification assays were Life Technologies, Abcam and Sigma Aldrich.

The median cost per single well for epigenetic modification assays undertaken in house was $0.75-$1.0 for biochemical assays versus $1-$2 for cellular assays.

Profiling against panels of epigenetic targets using biochemical or cellular assays were the aspects of epigenetic modification research most respondents were interested to outsource.

The median % of epigenetic modification primary screening outsourced in 2014 was ‘none'.

The median % of epigenetic modification profiling outsourced in 2014 was <10%.

The median total number of single wells outsourced to a fee-for-service provider for epigenetic primary screening and profiling was <100 wells in 2014.

The median budget allocated for outsourced epigenetic testing was $5K-$25K/lab in 2014.

A bottom-up model developed around respondent's annual budget for outsourced epigenetic modification testing and services estimated the global market to be around $4M in 2014.

The preferred fee-for-service providers of epigenetic modification profiling assay services were Life Technologies, Cisbio and Eurofins.

The full report provides the data, details of the breakdown of the responses for each question, its segmentation and the estimates for the future (2016). It also highlights some interesting differences, particularly between Pharma versus the other survey groups.

Table of Contents

  • Executive Summary
  • Table Of Contents
  • Respondent?fs Main Group Activity And Response To Survey
  • Respondent?fs Geographic Origin
  • Respondent?fs Company Or Organisational Origin
  • Respondent?fs Job Role
  • Respondent?fs Main Group Activity
  • Respondent?fs Main Research Discipline
  • Current Use Of Epigenetic Enzyme Screening Assays
  • Opinion On Current Status Of Epigenetic Targets
  • Therapeutic/Disease Areas Using Epigenetic Modification Assays
  • Level Of Priority Given To Epigenetic Modification Research
  • Key Epigenetic Modification Classes Of Most Interest Today
  • Key Epigenetic Modification Classes Under Investigation (1)
  • Key Epigenetic Modification Classes Under Investigation (2)
  • Main Sources/Origin Of Epigenetic Proteins Used
  • Stages In Drug Discovery Process Using Epigenetic Modification Assays
  • Epigenetic Modification Proteins That Have Adequate Biochemical Assays
  • Epigenetic Modification Proteins That Have Adequate Cellular Assays
  • Summary Of Survey Findings (1)
  • Preferred Biochemical Assay Format For Internal Work
  • Preferred Biochemical Assay Format When Outsourcing Testing
  • Preferred Cellular Assay Format For Internal Work
  • Preferred Cellular Assay Format When Outsourcing Testing
  • Preferred Biochemical Formats For Epigenetic Modification Assays
  • Preferred Cellular Formats For Epigenetic Modification Assays
  • Substrates Most Commonly Used For Epigenetic Enzyme Assays
  • Most Important Challenges In Epigenetic Modification Protein Assay Development
  • Specific Assay Challenges Encountered With Epigenetic Modification Proteins
  • New Tools Required to Drive Investigation Of Epigenetic Modification Assays
  • Major Limitations Of Screening Epigenetic Modification Proteins
  • Aspects Of Epigenetic Modification Drug Discovery Most Limiting Today
  • Changes In Limitations Of Epigenetic Modification Screening Assays Over Past Years
  • Number Of FTE?fs That Support In House Epigenetic Modification Research
  • Number Of Epigenetic Modification Targets Investigated In House
  • Number Of Epigenetic Modification Primary Screens (HTS) Per Year
  • Number Of Wells Per Primary Epigenetic Modification Screen
  • Approach To Primary Screening Of Epigenetic Modification Targets
  • % of Epigenetic Primary Screens That Are Biochemical/Enzyme Assays
  • Summary Of Survey Findings (2)
  • Epigenetic Modification Assay Reagent Budget
  • Breakdown Of Epigenetic Modification Reagent Budget Into Components
  • Epigenetic Modification Assay Reagents Market Estimate (1)
  • Epigenetic Modification Assay Reagents Market Estimate (2)
  • Epigenetic Modification Assay Reagents Market Estimate (3)
  • Main Sources Of Epigenetic Modification Assay Reagents (1)
  • Main Sources Of Epigenetic Modification Assay Reagents (2)
  • Cost Per Single Well For Epigenetic Modification Screening Assays
  • Aspects Of Epigenetic Modification Research Respondents Want To Outsource
  • Proportion Of Epigenetic Modification Primary Screening Assays Outsourced
  • Proportion Of Epigenetic Modification Profiling Assays Outsourced
  • Number Of Single Wells Outsourced For Epigenetic Modification Primary Screening
  • Number Of Single Wells Outsourced For Epigenetic Profiling
  • Outsourced Epigenetic Modification Testing Budget
  • Outsourced Epigenetic Modification Testing Market Estimate (1)
  • Outsourced Epigenetic Modification Testing Market Estimate (2)
  • Preferred Providers For Outsourced Epigenetic Profiling (1)
  • Preferred Providers For Outsourced Epigenetic Profiling (2)
  • Improvements Required And Unmet Needs In Epigenetic Modification Assays
  • Summary Of Survey Findings (3)
Back to Top